Enterococcus Faecalis

Most stool tests look for bugs you should not have in your gut. This one measures a bacterium you always have, but in a quantity that tells you whether your gut ecosystem is in balance.

E. faecalis (Enterococcus faecalis) is a normal resident of the human intestine. The reason to pay attention to its count is that overgrowth, not mere presence, is what consistently shows up in people with colorectal cancer, active Crohn disease, primary sclerosing cholangitis, and microbiome disruption from antibiotics or hospitalization.

What This Bacterium Is And What Stool PCR Measures

E. faecalis is a tough, oxygen-tolerant bacterium that lives in the mouth and gut of most healthy people. In a balanced microbiome it is typically described as subdominant, making up only a small fraction of the overall bacterial community. It earns its reputation as a pathobiont (a normal resident that can turn problematic) when it expands beyond that small share.

Stool PCR measures bacterial DNA directly from a stool sample, usually by amplifying a species-specific gene. Some labs report a relative abundance score, others a copy number per gram of stool. What you are reading is bacterial load, not symptoms, and not whether the organism is actively causing harm.

This is a research-grade measurement. There are no universally agreed-upon clinical cutpoints separating normal from abnormal. Most published evidence comes from case-control studies comparing patient groups, not from large healthy-population reference ranges. That makes a single reading useful as a starting point but never as a standalone diagnosis.

Colorectal Cancer Signal

Stool E. faecalis is often higher in people with colorectal cancer than in healthy controls. In a 650-person case-control study, the count was about 2.2 times higher in people with colorectal cancer than in healthy people. A smaller study found the average copy number in cancer cases was roughly 12 times higher than in healthy controls, with people who had polyps falling in between. That said, when researchers pool many shotgun metagenomic studies together, E. faecalis is not among the most consistently CRC-enriched fecal species (those tend to be organisms like Fusobacterium nucleatum, Parvimonas micra, and Peptostreptococcus stomatis), so the fecal signal for E. faecalis specifically is less replicated than the tissue-based signal.

What this means for you: a higher count is a signal worth watching, not a cancer diagnosis. Some prospective work suggests fecal E. faecalis levels can be unstable over time and are not always clearly tied to large adenomas or cancer in individuals. The connection at the population level is real, but it does not translate cleanly into individual risk prediction yet. Standard colorectal cancer screening (FIT, Cologuard, or colonoscopy) remains the first line.

Inflammatory Bowel Disease

In Crohn disease and ulcerative colitis, stool E. faecalis is consistently higher than in healthy controls. In Crohn disease specifically, higher counts track with disease activity scores and fecal calprotectin, a separate marker of gut inflammation. A study of people with inflammatory bowel disease found a statistically significant positive correlation between high-level E. faecalis colonization and the Crohn Disease Activity Index (R = 0.31, P = 0.01), as well as with fecal calprotectin (P = 0.016).

If you have IBD, a rising E. faecalis count alongside rising calprotectin or symptoms can add weight to the picture of active inflammation. It is not a substitute for established markers like calprotectin, but it can support the trend.

Primary Sclerosing Cholangitis And Liver Disease

Primary sclerosing cholangitis (a chronic disease that scars the bile ducts) shows a particularly strong gut-liver connection. In a 337-person study, people with this condition who had high stool enterococci abundance had a lower probability of survival without needing a liver transplant. Higher fecal cytolysin, a toxin produced by some E. faecalis strains, was also linked to lower overall survival.

This is one of the clearest cases where the gut bacterium appears to influence an organ outside the intestine. It points to the broader idea that what is happening in your stool can quietly shape what is happening in your liver, joints, and immune system.

Antibiotic And Hospital Expansion

E. faecalis is notorious for blooming after antibiotics that wipe out its competitors. In a large hospital microbiome study, both meropenem and metronidazole exposure were associated with a higher rate of transitioning into an Enterococcus-dominated stool state. An earlier transplant cohort found metronidazole roughly tripled the odds of enterococcal domination. After stem cell transplantation, the share of enterococci in stool jumped from about 21% in people who stayed well to 74% in those with active gut graft-versus-host disease.

Hospitalization, chemotherapy, and severe illness like sepsis also push the count up. Preliminary work (a preprint, not yet peer-reviewed) has suggested that fecal E. faecalis enrichment may be among the stronger microbiome-based predictors of COVID-19 severity. The mechanism is the same in each case: the rest of the microbial community gets knocked down, and this organism takes advantage of the empty space.

A Normal Resident That Becomes A Pathobiont

It can feel contradictory that a normal gut bacterium is also associated with cancer, IBD, and worse survival in liver disease. The framework that resolves this: E. faecalis is not a good-or-bad organism, it is a context-dependent one. At low levels it sits quietly in a balanced ecosystem. When something disrupts the surrounding community (antibiotics, inflammation, a tumor microenvironment, hospitalization), it expands, produces reactive oxygen species and virulence factors like cytolysin and gelatinase, and starts contributing to inflammation and tissue damage. The count, not the presence, is what matters.

When Results Can Be Misleading

Stool PCR is sensitive but not always specific to disease. A single reading can mislead in several ways.

• Recent antibiotics: courses in the prior weeks to months can transiently bloom E. faecalis without indicating any underlying disease. Most healthy adults recover species richness within about 2 months of stopping antibiotics, though some taxonomic and resistance-gene changes can persist for 6 to 12 months.
• Hospitalization or acute illness: sepsis, chemotherapy, and stem cell transplant routinely push enterococci up. A reading taken during or shortly after these events reflects the stress, not your baseline.
• Healthy carriage: in surveys of healthy people, stool pathogen panels often return positive results without symptoms. A detectable signal does not equal infection, especially in adults without GI complaints.
• Sample handling and DNA extraction: stool contains substances that interfere with PCR. The accuracy of quantification depends on the lab's extraction method, so values from different labs are not directly comparable.

Tracking Your Trend

A single E. faecalis count is hard to interpret on its own. The number gains meaning when you compare it to your own prior readings and to the rest of your microbiome panel. If you are healthy and curious about your gut, a baseline plus a follow-up in 3 to 6 months gives you something to compare. If you have IBD, recurring digestive symptoms, or a known colorectal cancer risk, annual or twice-yearly tracking alongside calprotectin and other microbiome markers makes the signal usable.

Retest after any major intervention that could shift the microbiome: a course of antibiotics, a new probiotic or prebiotic regimen, a significant diet change, or a hospital stay. Wait at least 4 to 6 weeks after antibiotics before retesting so you are reading your settled state, not the acute aftermath.

What An Abnormal Result Should Prompt

An elevated E. faecalis count by itself is not a diagnosis and does not justify treatment with antibiotics. Antibiotics often make enterococcal overgrowth worse, not better. Instead, treat it as a prompt to look at the broader picture.

• Look at companion markers: elevated fecal calprotectin alongside high E. faecalis points toward active inflammation and warrants a GI workup. Low microbial diversity, expansion of other pathobionts, or loss of butyrate producers strengthens the dysbiosis picture.
• Review recent exposures: if antibiotics, hospitalization, or major illness occurred in the past few months, that likely explains the bloom and a repeat test after recovery is the right next step.
• Consider GI specialty input: persistent elevations alongside symptoms (bloody stools, unexplained weight loss, abdominal pain, family history of colorectal cancer or IBD) warrant a conversation with a gastroenterologist about colonoscopy, calprotectin trending, or imaging.
• Do not skip standard screening: if you are over 45 or have a family history, FIT or colonoscopy remains the appropriate cancer screening, regardless of what your stool microbiome shows.